Hazard Information | Back Directory | [Uses]
ADRA1D receptor antagonist 1 is a potent, selective and orally active α1D adrenoceptor antagonist, with a Ki of 1.6 nM[1]. | [in vivo]
ADRA1D receptor antagonist 1 (4.4 μg/kg; i.v.) dose-dependently decreases the non-voiding bladder contractions during the urinary storage phase in rats with BOO[1].
Animal Model: | Rat with bladder outlet obstruction (BOO)[1] | Dosage: | 4.4 μg/kg | Administration: | Intravenous injection | Result: | Dose-dependently decreased the non-voiding bladder contractions during urinary storage phase in rats with BOO. |
| [References]
[1] Sakauchi N, et al. Discovery of 5-Chloro-1-(5-chloro-2-(methylsulfonyl)benzyl)-2-imino-1,2-dihydropyridine-3-carboxamide (TAK-259) as a Novel, Selective, and Orally Active α1D Adrenoceptor Antagonist with Antiurinary Frequency Effects: Reducing Human Ethe DOI:10.1021/acs.jmedchem.5b01528 |
|
Company Name: |
BOC Sciences
|
Tel: |
1-631-485-4226; 16314854226 |
Website: |
https://www.bocsci.com |
Company Name: |
MedChemExpress
|
Tel: |
021-58955995 |
Website: |
www.medchemexpress.com |
|